Global Live Attenuated Vaccines Market - 2025-2033

Global Live Attenuated Vaccines Market: Industry Outlook

The global live attenuated vaccines market reached US$ 16.80 Billion in 2023, with a rise of US$ 17.82 Billion in 2024 and is expected to reach US$ 31.56 Billion by 2033, growing at a CAGR of 6.6% during the forecast period 2025-2033.

The live attenuated vaccines market is experiencing significant growth due to the increasing prevalence of infectious diseases, increased immunization efforts, and advancements in vaccine research. These vaccines, which use a weakened form of the pathogen to stimulate a strong immune response, are crucial for global immunization programs.

The demand for effective and affordable vaccine solutions is boosted by public health risks, particularly in developing regions. The market is also influenced by governmental and non-governmental initiatives, such as the WHO, UNICEF, and Gavi, which promote universal vaccine coverage. Technological innovations in vaccine storage, delivery systems, and cold chain logistics have improved the viability of live attenuated vaccines, even in resource-limited settings.

Emerging market players and public-private partnerships are accelerating vaccine development pipelines and expanding global distribution networks. The North America region is expected to be a key growth area due to its large population base, high disease burden, and improved healthcare access.

Global Live Attenuated Vaccines Market Dynamics: Drivers & Restraints

Driver: Rising prevalence of infectious diseases

The increasing prevalence of infectious diseases like measles, tuberculosis, rubella, and influenza is driving global demand for live attenuated vaccines. These diseases pose significant public health risks, especially in developing countries with limited healthcare access. The emergence of new pathogens and frequent outbreaks emphasizes the need for robust immunization strategies. Live attenuated vaccines, mimicking natural infections, are prioritized in national immunization programs. This escalating disease burden and global efforts to reduce morbidity and mortality rates drive market growth.

For instance, the WHO reported 8.2 million new TB cases in 2023, the highest since 1995. The total number of TB cases increased to 10.8 million, up from 10.7 million in 2022 and 10.1 million in 2020. However, the gap between new and notified cases decreased to 2.7 million, indicating improved access to treatment.

Hence, the rise in prevalence highlights the need for effective vaccination strategies and live attenuated vaccines. The reduced gap in notified cases indicates improved healthcare outreach, supporting vaccine deployment, and addressing the growing public health challenge.

Driver: High efficacy and long-term immunity

Live attenuated vaccines are highly effective and cost-effective in preventing severe outcomes of infectious diseases. They induce long-lasting immunity with fewer doses by using a weakened form of the pathogen, replicating natural infections. This results in sustained protection over many years, often with just one or two doses. Healthcare providers and public health agencies prefer these vaccines, as they offer long-term immunity that enhances individual protection and contributes to herd immunity.

Restraint: Cold chain and storage challenges

The global live attenuated vaccines market faces significant challenges due to its stringent cold chain requirements. These vaccines contain weakened viruses or bacteria that are sensitive to heat, light, and freezing conditions. To maintain their potency and safety, they must be stored and transported at controlled temperatures between 2°C and 8°C. This poses logistical and cost-related challenges, especially in low- and middle-income countries with inadequate refrigeration infrastructure. Any break in the cold chain can reduce vaccine effectiveness or waste, hindering market growth and accessibility.

Opportunity: Expansion in emerging markets

The global live attenuated vaccines market is experiencing significant growth in emerging markets due to rising healthcare awareness, government investment in immunization programs, and the increasing burden of infectious diseases. Countries in Asia-Pacific, Latin America, and Africa are experiencing improved healthcare infrastructure and greater access to medical services.

International organizations like Gavi, WHO, and UNICEF are funding vaccination campaigns and strengthening supply chains in these regions. Live attenuated vaccines are well-positioned to meet public health needs, allowing manufacturers to penetrate untapped markets and drive long-term growth.

For more details on this report, Request for Sample

Global Live Attenuated Vaccines Market Segment Analysis

The global live attenuated vaccines market is segmented based on product type, indication, route of administration, age group, distribution channel, and region.

Product Type

The viral vaccine segment from the product type is expected to hold 58.14% of the live attenuated vaccines market

The viral vaccine segment is driving global growth in the live attenuated vaccines market due to its crucial role in preventing deadly viral infections. Diseases like measles, mumps, rubella, varicella, yellow fever, and influenza have historically caused significant morbidity and mortality, particularly in pediatric and immunocompromised populations. Live attenuated viral vaccines offer strong immunogenicity, requiring fewer doses for long-term protection. They induce a robust immune response, closely mimicking natural infections, making them highly effective. The inclusion of viral vaccines in national immunization schedules continues to drive demand.

For instance, in August 2024, Indian Immunologicals Limited (IIL) developed a live-attenuated needle-free intra-nasal booster vaccine against the Sars-CoV-2 virus, which causes COVID-19. The vaccine, developed in collaboration with Griffith University in Australia, uses codon deoptimisation technology. Codon deoptimisation is considered highly efficient and safe for virus attenuation, and the attenuated virus is expected to present all antigens and mimic natural infection.

Global Live Attenuated Vaccines Market - Geographical Analysis

North America dominated the global Live Attenuated Vaccines market with the highest share of 42.3% in 2024

North America leads the global live attenuated vaccines market due to advanced healthcare infrastructure, high immunization coverage, and strong government support. Major pharmaceutical companies like Merck & Co., Pfizer, and Johnson & Johnson contribute to research, development, and distribution. Proactive disease surveillance systems and favorable reimbursement policies encourage vaccine uptake. Public health programs and strategic stockpiling by the U.S. government fuel demand. Continuous innovation and regulatory support from agencies like the FDA ensure a stable market environment for new and improved live attenuated vaccine formulations.

For instance, in September 2024, FluMist, a needle-free nasal spray, was approved in the US as the only self-administered influenza vaccine. The FDA approved it for adults up to 49 years old or individuals aged 2-17 under a parent or caregiver. The approval was based on a usability study showing that individuals over 18 can self-administer or administer FluMist to eligible individuals.

Asia-Pacific is the global live attenuated vaccines market with a market share of 21.5% in 2024

The Asia Pacific region is experiencing rapid growth in the live attenuated vaccines market due to its large population, high infectious disease burden, and focus on preventive healthcare. Governments in countries like India, China, Indonesia, and Vietnam are expanding immunization programs and investing in cold chain logistics to improve vaccine accessibility. Key regional manufacturers like Serum Institute of India and Bharat Biotech enhance local production capabilities and affordability. International health organizations and mass vaccination campaigns help bridge healthcare delivery gaps.

For instance, in February 2024, Takeda and Biological E. Limited announced a strategic partnership to expedite access to QDENGA( Live attenuated) multi-dose vials (MDVs) for procurement by governments in endemic countries by 2030. These doses offer economic and logistical advantages by minimizing packaging and storage expenses and reducing medical and environmental waste. BE will ramp up its manufacturing capacity to 50 million doses a year, accelerating Takeda's efforts to manufacture 100 million doses within a decade.

Global Live Attenuated Vaccines Market - Key Players

The major global players in the live attenuated vaccines market include GlaxoSmithKline Plc, Merck & Co., Inc., Johnson & Johnson, Sanofi, CSL Limited, Serum Institute of India Pvt. Ltd., AstraZeneca, Bavarian Nordic Inc., BioDiem, and Bharat Biotech, among others.

Global Live Attenuated Vaccines Market – Key Developments

• In May 2025, the European Medicines Agency (EMA)'s safety committee (PRAC) initiated a review of Ixchiq, a live attenuated chikungunya vaccine, following reports of serious adverse events in elderly individuals. The exact cause and relationship with the vaccine remain unknown. Currently, 17 serious adverse events, including two fatal cases, have been reported globally in individuals aged 62-89.

• In May 2025, Japanese pharmaceutical company Takeda plans to launch its dengue vaccine, Qdenga, in India next year, in collaboration with Hyderabad-based Biological E. Clinical trials are ongoing, and the company aims to secure a license by 2026. India could receive the vaccine as early as next year. Takeda's Global Vaccine Business Unit president, Derek Wallace, announced that the $23 billion company will adopt a tiered pricing model to maximize access to the vaccine.